| May 28 |
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
| May 24 |
biolinerx Q1 Earnings Preview
|
| May 24 |
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
|
| May 22 |
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
|
| May 17 |
BioLineRx receives Nasdaq minimum bid price notification
|
| May 17 |
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
|
